Study	Total	Expe Mean	rimental SD		Mean	Control SD	Mean Difference	MD	95%-CI		Weight (random)
g = 12-13months Bachert 2019 SINUS-52 Bertlich 2022 Torretta 2022 Fixed effect model Random effects model Heterogeneity: $I^2 = 96\%$, $\tau^2 = 159.4665$,	75 80 450	16.60 13.49	19.1600 10.9000 10.8700	18	66.90	19.7200 15.2000 18.6600	*	-50.30 -46.62 -35.81	[-31.63; -25.35] [-57.74; -42.86] [-51.35; -41.89] [-38.28; -33.35] [-56.19; -26.95]	3.8% 9.4% 34.5%	9.1% 7.7% 8.6% 25.4%
g = 3-4months Bachert (2016) Haxel 2022 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.35$			11.0000 10.0000			18.2000 19.9000	*	-33.30 -31.41	[-36.21; -20.99] [-39.54; -27.06] [-36.24; -26.59] [-36.24; -26.59]	9.0%	7.7% 8.2% 15.8%
g = 6-8months Bachert (2016) Bachert 2019 SINUS-24 Bachert 2019 SINUS-52 2wks Bachert 2019 SINUS-52 2wks-4wks Bertlich 2022 Haxel 2022 Torretta 2022 Fixed effect model Random effects model Heterogeneity: I ² = 90%, τ ² = 60.3375, μ	143 150 145 75 49 80 671	18.58 23.89 23.89 20.70 22.00 18.61	15.2000 14.9200 18.7700 18.7700 13.5000 8.0000 15.7600	143 150 145 43 49	48.00 50.16 51.89 66.90 57.30	18.2000 20.1600 19.7200 21.0500 15.2000 19.9000 18.6600	*	-29.42 -26.27 -28.00 -46.20 -35.30 -41.50 -32.31	[-28.15; -11.05] [-33.53; -25.31] [-30.63; -21.91] [-32.59; -23.41] [-51.67; -40.73] [-41.31; -29.29] [-46.85; -36.15] [-34.24; -30.38] [-38.63; -26.37]	11.1% 10.0% 7.0% 5.8% 7.3% 56.5%	7.3% 8.8% 8.8% 8.7% 8.4% 8.2% 8.5%
Fixed effect model Random effects model Heterogeneity: $I^2 = 91\%$, $\tau^2 = 67.1692$, μ Residual heterogeneity: $I^2 = 92\%$, $\rho < 0$	1200			1112			-40 -20 0 20 40		[-34.89; -31.99] [-39.42; -29.57]		100.0%

Supplementary Fig. 5. Changes in SNOT-22 scores from baseline (dupilumab). The mean post-treatment differences in the SNOT-22 scores at 3, 6, and 12 months of treatment [9,12,13,16,17]. Totals: numbers of participants per group. SNOT-22, 22-item SinoNasal Outcome Test; SD, standard deviation; MD, mean difference; CI, confidence interval.